Optimization of vaccine production for animal health

Abstract

Vaccines on the basis of mammalian cell cultures are of major importance for human and animal health. Therefore efforts are undertaken for the improved production of more effective vaccines. Of course, the main purpose of all these approaches is to save lives and improve the quality of life for human beings. However, there is also some remarkable effort in the food industry and the associated animal production, especially in the case of some Flaviviridal viruses (BVD), where > 80% of all cattle herds are found to be infected. These viruses can cause tremendous economic losses of calfs and embryos (Ames, 1990). Because of these facts, there is a continuous endeavour for improving the manufacturing of therapeutics or preventing agents such as vaccines for the treatment of cattle. The competitive economic situation and the specific market demands still require effective and high yield production methods, especially in the case of one of the most widespread viral diseases in cattle like BVD (Ames, 1990). We have succeeded in establishing an improved method for the production of BVD on the basis of a continuous fermentation mode, that consist of modifications of the corresponding process and media improvements.

Bovine neonatal pancytopenia - Comparative proteomic characterization of two BVD vaccines and the producer cell surface proteome (MDBK)

“…One prominent example is ATP Synthase, an ubiquitous protein of the oxidative phosphorylation pathway which was considered to be an exclusively mitochondrial protein for decades, but was discovered recently on the cell surface of a great variety of cell types [23]. MDBK cells are often used as culture system for growing attenuated viruses in vaccine production [24], e.g. BVDV [9].…”

Single dilution Avidity-Blocking ELISA as an alternative to the Bovine Viral Diarrhea Virus neutralization test

“…BVDV Singer and NADL strains, MDBK and Spodoptera frugiperda (SF21) cells were obtained from ATCC. BVDV stocks were produced by infecting MDBK cells, following standard procedures (Marzocca et al, 2007;Noe et al, 1994). Monoclonal antibody (MAb) 2.9.H is produced by ICT Milstein-CONICET (Buenos Aires, Argentina) and has been applied previously to a BVDV indirect ELISA (Marzocca et al, 2007) and to an antigen ELISA (Pecora et al, 2009).…”

Model Simulation and Analysis of Perfusion Culture of Mammalian Cells at High Cell Density

“…Perfusion culture of animal cells has gained industrial attention for the production of biopharmaceutic products such as growth factors, vaccines, and monoclonal antibodies due to its high productivity, better cell physiology control, and several other advantages compared to batch or fed-batch cultures (Lubiniecki, 1990;Kempken et al, 1991;Noe et al, 1994;Perrin et al, 1995;Ozturk, 1996;Hu and Aunins, 1997;Kadouri and Spier, 1997). Consequently, several recent studies have investigated the growth kinetics, product formation, and process monitoring and control of perfusion cultures (Seamans and Hu, 1990;Shirai et al, 1992;Schmid et al, 1992;Hiller et al, 1993;Banik and Heath, 1995a,b;Konstantinov et al, 1996;Ozturk et al, 1997).…”